» Articles » PMID: 3927520

Teratogenic Valproic Acid Concentrations: Infusion by Implanted Minipumps Vs Conventional Injection Regimen in the Mouse

Overview
Specialties Pharmacology
Toxicology
Date 1985 Sep 15
PMID 3927520
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

The dosage-regimen-dependent teratogenicity as well as plasma and tissue levels of the antiepileptic drug valproic acid (VPA) were studied in the mouse by comparing various injection regimens and infusion of the drug via implanted osmotic minipumps. Concentrations of 225-248 micrograms VPA/ml maternal plasma (about 2X above the therapeutic concentration range) and 70-75 micrograms VPA/g gestational material (on gestation Day 8) resulted in a significant incidence of neural tube defects (exencephaly in the mouse). Similar effects were produced if those concentrations were reached several times after multiple injections or by steady-state application via implanted pumps. A single injection was less effective than multiple injections, although drug accumulation did not occur. The doses (or area under the concentration-time curve values) did not correlate with the teratogenic response of the different administration regimens: much higher (factor 10) doses were needed with the infusion regimen to produce exencephaly rates comparable to those obtained with the injection regimen. The pattern of embryotoxicity was also schedule dependent: steady-state concentrations produced predominantly embryolethality and fetal weight retardation, while intermittent injections produced a high incidence of exencephaly (up to 60% of live fetuses). The dose of VPA (and the areas under the concentration-time curves) correlated with the embryolethality and fetal weight retardation of the drug, while the peak or steady-state concentrations reached in mother and gestational material correlated with the incidence of neural tube defects.

Citing Articles

Predictors of valproic acid steady-state serum levels in adult and pediatric psychiatric inpatients: a comparative analysis.

Avrahami M, Liwinski T, Eckstein Z, Peskin M, Perlman P, Sarlon J Psychopharmacology (Berl). 2024; 241(9):1883-1894.

PMID: 38733528 DOI: 10.1007/s00213-024-06603-y.


Pan HDACi Valproic Acid and Trichostatin A Show Apparently Contrasting Inflammatory Responses in Cultured J774A.1 Macrophages.

Ubah U, Triyasakorn K, Roan B, Conlin M, Lai J, Awale P Epigenomes. 2022; 6(4).

PMID: 36412793 PMC: 9680436. DOI: 10.3390/epigenomes6040038.


Embryonic Hypotaurine Levels Contribute to Strain-Dependent Susceptibility in Mouse Models of Valproate-Induced Neural Tube Defects.

Steele J, Lin Y, Chen N, Wlodarczyk B, Chen Q, Attarwala N Front Cell Dev Biol. 2022; 10:832492.

PMID: 35265619 PMC: 8898900. DOI: 10.3389/fcell.2022.832492.


Chromatin Imbalance as the Vertex Between Fetal Valproate Syndrome and Chromatinopathies.

Parodi C, Di Fede E, Peron A, Vigano I, Grazioli P, Castiglioni S Front Cell Dev Biol. 2021; 9:654467.

PMID: 33959609 PMC: 8093873. DOI: 10.3389/fcell.2021.654467.


The Placental Barrier: the Gate and the Fate in Drug Distribution.

Tetro N, Moushaev S, Rubinchik-Stern M, Eyal S Pharm Res. 2018; 35(4):71.

PMID: 29476301 DOI: 10.1007/s11095-017-2286-0.